The world market for pharmaceuticals used in infertility management will garner $1.5 billion in revenues in 2005, according to a new market research report, Markets in Human Reproductive Medicine: Contraception and Infertility Management released earlier this month from Kalorama Information. The increasing utilization of infertility treatments, the availability of more effective recombinant products replacing older urine-derived ones, and the advent of more convenient delivery devices are among the forces driving the market.
The new study, Markets in Human Reproductive Medicine: Contraception and Infertility Management , forecasts steady growth in the infertility management market, which is dominated by a few major players and is highly competitive. Product innovation within existing classes of drugs will be the main basis of competition in the near term, but revolutionary products are on the horizon.
"Researchers are upbeat about the prospects for new discoveries in reproductive science in the 21st century,"notes Anne Anscomb, the author of the report. "Possible oral FSH, GnRH antagonists for manipulation of pituitary-gonadal function, and even treatments arising from research in other fields, are among some of the most intriguing developments."
In addition to pharmaceutical developments, the report also details markets and progress in assisted reproductive technologies (ARTs) such as IVF, GIFT, and ZIFT. The market for these technologies, which remain very expensive, is currently larger than the infertility pharmaceutical market. However, these technologies face multiple challenges including ethical concerns over the sharp increase in multifetal gestations and the nature and amount of reimbursement the procedures enjoy.
